Compare Medpace Holdings Inc (MEDP) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Schwab US Large Cap Growth ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 3.9× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 8,554,399). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| MEDP | SCHG | |
|---|---|---|
Market Cap | $16.82B | $65.01B |
Volume | 223,093 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $630.19 | $36.93 |
52-Week Low | $393.42 | $28.10 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SCHG trades at $36.74, down 0.35% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low 0.03% expense ratio and its focus on large-cap growth stocks, though concentration in top holdings remains a structural consideration.
The outlook for SCHG remains positive given its growth orientation and cost efficiency, though investors should monitor concentration risks in top holdings. Market leadership in growth sectors and competitive fees support long-term potential, while sensitivity to tech sector volatility presents the primary near-term risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
